ArticleDiscover oncology2025
Factors associated with herbal medicine use among patients with cancer attending a tertiary hospital in Southwestern Uganda: a cross-sectional study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of Phytotherapy for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerbal medicine use among patients with cancer is prevalent particularly in low- and middle-income countries. However, concerns about safety and potential interactions with chemotherapy emphasize the need to understand the prevalence and factors associated with herbal medicine use in this setting. Therefore, the aim of this study was to determine the prevalence and factors associated with herbal medicine use among patients with cancer at Mbarara Regional Referral Hospital (MRRH).
methodsWe conducted a cross-sectional study between September 2023 and November 2023 at the oncology unit of MRRH. Data analysis was done using SPSS version 27. The demographic characteristics of the study participants were analyzed descriptively and presented as frequency and percentage. The prevalence of herbal medicine use was presented as a percentage. We employed both bivariate and multivariate logistic regression to determine the factors associated with herbal medicine use and statistical significance was considered at a p-value < 0.05.
resultsA total of 358 patients were approached for the study and data from 303 participants was used for analysis. The overall prevalence of herbal medicine use among patients with cancer attending the MRRH was 56.8% (172/303). Of the 172 patients with cancer who use herbal medication, 46.4% (80/172) use herbal medication alongside conventional medication. Factors associated with herbal medicine use among the study participants include: stage III cancer (aOR = 2.7, 95% CI:1.3-5.3; p-value = 0.005), Stage IV cancer (aOR = 3.1, 95% CI: 1.5-6.3; p-value = 0.003), having a comorbid condition (aOR = 1.8, 95% CI:1.1-2.9; p-value = 0.026), and having received three or more cycles of chemotherapy (aOR = 2.5, 95% CI: 1.2-5.0; p-value = 0.014).
conclusionThe high prevalence of herbal medicine use among patients with cancer at MRRH indicates a strong reliance on complementary medicine, especially among those with advanced cancer and multiple comorbidities. Addressing this requires education on safe herbal medicine use and regular monitoring to ensure patient safety and improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.